đź“Š Evidence-Based Reference
Selectra Lead Implantation System
Summary: The Selectra Lead Implantation System by Biotronik is used for conduction system pacing, particularly left bundle branch area pacing (LBBAP). Key evidence highlights its effectiveness and safety in mimicking natural cardiac conduction.
FDA Clearance Information
Pathway ?
510(k)
Number ?
K222037 ↗
Decision Date ?
July 19, 2022
Product Code ?
DQY Catheter, Percutaneous
Device Class ?
Class 2
Evidence ?
0 studies
The Selectra Lead Implantation System was cleared by the FDA via the 510(k) pathway on July 19, 2022. It is manufactured by Biotronik and classified as a Class 2 device under product code DQY.
What It Is
The Selectra Lead Implantation System is designed for conduction system pacing, specifically targeting the left bundle branch area. It aims to provide a more physiological pacing alternative compared to traditional right ventricular pacing.
FDA-Cleared Indications
- For percutaneous introduction and positioning of compatible cardiac pacing leads within the heart.
- For use with compatible pacemaker systems during transvenous cardiac lead implantation.
- The system is an accessory for cardiac pacing lead placement and is not itself a pacemaker or pacing lead.
Clinical Applications
- Transvenous implantation of compatible right-sided cardiac pacing leads.
- Catheter-based positioning of pacing leads in the right atrium or right ventricle.
- Use as part of a compatible pacemaker system during implantation or lead revision.
- Access and delivery support for lead placement when the selected lead and generator labeling permit the intended pacing configuration.
Reported off-label uses
- Conduction-system pacing approaches such as His-bundle pacing or left bundle branch area pacing may be performed with compatible systems, but the specific application should be confirmed against the current device, lead, and pacemaker labeling.
Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.
Evidence Summary
The literature includes a mix of RCTs, prospective, retrospective, and case series studies, with a total of 9 studies published between 2023 and 2025. These studies explore the efficacy and safety of the Selectra system in various clinical settings.
Reported Outcomes
Published studies report that the Selectra Lead Implantation System is effective in achieving stable pacing thresholds and mimicking natural cardiac conduction. Left bundle branch area pacing using this system has shown favorable outcomes in terms of pacing stability and reduced risk of heart failure.
Safety Profile
Reported complications include typical risks associated with lead implantation, such as lead dislodgement and infection. However, the studies indicate that the Selectra system maintains a safety profile comparable to other pacing systems.
Evidence Limitations
The current evidence is limited by the relatively short follow-up periods and small sample sizes in some studies. Further research is needed to assess long-term outcomes and compare the system's efficacy against other pacing modalities.
Practical Considerations
- The system is used through venous access and under fluoroscopic imaging; implant technique depends on the selected lead, cardiac anatomy, and pacing objective.
- Compatibility must be confirmed with the intended pacing lead and pulse generator, including connector type, lead diameter, sheath dimensions, and the manufacturer’s compatibility instructions.
- The system is a delivery accessory and does not provide pacing by itself. It should be used only by clinicians trained in transvenous cardiac lead implantation.
- MRI eligibility depends on the complete implanted pacemaker system, including the generator, leads, and lead positions; the delivery system itself is not the factor that determines MRI conditional status.
- Potential procedural risks include venous or cardiac perforation, bleeding, infection, arrhythmia, lead dislodgement, pneumothorax, and the need for lead repositioning or revision.
Frequently Asked Questions
What are the clinical indications for Selectra Lead Implantation System?
The system is indicated for conduction system pacing, particularly in patients requiring left bundle branch area pacing to mimic natural cardiac conduction.
What outcomes have been reported in clinical studies?
Studies have reported effective pacing thresholds and stability, with reduced risks of heart failure and atrial fibrillation compared to traditional pacing methods.
What complications have been reported?
Safety data indicate risks such as lead dislodgement and infection, but overall, the system has a safety profile similar to other pacing systems.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.